In a nutshell The authors aimed to determine the changes in cognitive performance (CP) after 6 months of hormone therapy with luteinizing hormone-releasing hormone (LHRH) analogues. The authors concluded that CP in men with prostate cancer does not appear to be affected following 6 months of LHRH treatment. Some background Androgen...
Read More
In a nutshell The authors aimed to determine the change in bone density in patients who received luteinizing hormone-releasing agonists (LHRHa, treatments that reduce testosterone production in the body) compared to estradiol patches (patches that deliver the hormone estradiol). The authors concluded that EPs reduce the loss of bone density and...
Read More
In a nutshell This study investigated the risk of heart attacks and diabetes among prostate cancer patients, with and without co morbidities, receiving androgen deprivation therapy (ADT). Some background Androgen-deprivation therapy (ADT) is a commonly used treatment for prostate cancer. Since prostate cancer growth is stimulated by androgen...
Read More
In a nutshell This article looked at the benefit on survival of short term hormone therapy called androgen deprivation therapy (ADT), in combination with radiation therapy, for the treatment of patients with prostate cancer. Some background Prostate specific antigen (PSA) is a protein produced by the prostate gland. Men with a healthy...
Read MoreIn a nutshell This phase 3 trial aims to determine if androgen suppression along with high dose proton radiation therapy offers more benefit than proton radiation therapy alone. The main outcome investigated is freedom from treatment failure. The details Freedom from treatment failure represents successful treatment with no local cancer...
Read More
